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Abstract
Malaria remains a major health burden especially for the developing countries. Despite concerted efforts at
using the current control tools, such as bed nets, anti malarial drugs and vector control measures, the disease is
accountable for close to a million deaths annually. Vaccines have been proposed as a necessary addition to the
armamentarium that could work towards elimination and eventual eradication of malaria in view of their histori-
cal significance in combating infectious diseases. However, because malaria vaccines would work differently
depending on the targeted parasite stage, this review addresses the potential impact various malaria vaccine
types could have on transmission. Further, because of the wide variation in the epidemiology of malaria across
the endemic regions, this paper proposes that the ideal approach to malaria control ought to be tailor-made
depending on the specific context. Finally, it suggests that although it is highly desirable to anticipate and aim
for malaria elimination and eventual eradication, many affected regions should prioritize reduction of mortality
and morbidity before aspiring for elimination.
Background
Malaria transmission is falling in some parts of Africa as
anti-malarials, bed nets and other vector control mea-
sures become more widely available [1-4]. However,
malaria disease continues to be a major public health
disaster with persistent transmission in vast areas and it
is clear that additional control measures are required.
Indeed epidemiological data indicates that malaria is still
a global health priority and the statistics of estimated
5 billion people exposed and close to 1 million deaths
year remain valid [5-7]. This is especially important in
the vast parts of sub-Saharan Africa where the social
and ecological environments render current control
tools blunt. Recent successes in malaria control using
other approaches highlight the need and the potential
impact that could be gained from an efficacious vaccine
[8-10]. Historically, vaccination has proved to be one of
the most effective approaches to controlling infectious
diseases and many authorities believe that it will not be
possible to move from control to elimination without
the addition of a malaria vaccine to the armamentarium
[9]. However, despite concerted international efforts, an
efficacious vaccine against malaria remains elusive.
The leading malaria vaccine candidate in development
RTS,S, which is currently undergoing phase III field eva-
luation in African children, has progressed based on
demonstrated efficacy against clinical malaria recently
reported to be around 50% in the field [11]. This good
news of a possible vaccine against malaria in the fore-
seeable future has revived the possibility of enhanced
malaria control and perhaps incited the call for malaria
elimination and eventual eradication. However, it is
important to examine current aspirations for malaria
elimination in the light of key historical experiences and
scientific facts.
Following the Eighth World Health Assembly resolu-
tion on transition from malaria control to its eradica-
tion, interruption of malaria transmission was achieved
in many countries of the temperate belt, and mortality
from the disease decreased dramatically. By 1970, about
1 billion people were freed from the risk of malaria, but
it had already become clear during the 1960’st h a tt h e
available methods of control would not interrupt
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point of note here is that expectations from control
measures ought to be based on the realistic possibility
of what available tools can achieve. Figure 1 describes
the relevant key terminology applicable to malaria
elimination.
How would a vaccine against malaria affect
transmission?
Transmission can be expressed in terms of simplified
mathematical models based on easy to visualize para-
meters, the most useful of which is the Macdonald
model [15]. This model describes the concept of basic
case reproduction rate (R0), which, in short, is the num-
ber of secondary cases arising from a single case in a
fully susceptible human population. It is a tool for
understanding and a way of thinking, but it cannot be
accurately applied in field situations [16]. Based on the
possible transmission dynamic factors in the Macdonald
formula, this review looks at the potential impact of vac-
cines targeting the various malaria parasite stages would
have on the basic case reproduction rates.
Figure 2 shows the Macdonald mathematical formula
and the summarized meaning of the basic reproduction
rate R0.
Pre-erythrocytic vaccines
Ideally, pre-erythrocytic vaccines would induce some
form of sterile protection that prevents infection by the
sporozoite beyond the liver stage [1,17-19]. However, a
review of the global malaria vaccine pipeline [20] shows
that all the current candidate vaccines have a profile
aiming at “partial protection” against malaria episodes
meaning that at best, they would not completely inter-
rupt the malaria parasite cycle in all vaccinees. The irra-
diated sporozoite vaccine approach is thus far the only
one that has shown to be highly efficacious at protection
of humans as well as animals, but this protection is yet
to be demonstrated in malaria endemic populations
[21,22]. The most advanced candidate vaccine RTS,S
recently showed an adjusted efficacy against clinical epi-
sodes of malaria at 53% (95% CI 28-69; P<0.001) in
Kenyan and Tanzanian children [11].
Such pre-erythrocytic stage vaccines would impact
transmission by reducing both “b” and “h” and thus
overall, reduce R0 by a proportion that could possibly
correlate to its protective efficacy. It is difficult at this
stage to assume that such an impact will roll on to
either affect the length of the sporogonic cycle or survi-
val rate in mosquitoes. What is apparent however, is
that other control measures, such as ITNs [1,23-25], use
of repellants [26,27], indoor residual sprays [28,29] and
indeed prophylactic anti-malarial drug usage [30-32],
would be synergistic to pre-erythrocytic vaccine effects.
In the Macdonald model, these control methods would
contribute to reductions in R0 by additionally pulling
both “a” and “m” lower and ultimately shrinking “h”
which respectively, are the frequency of mosquito bites,
Figure 1 Definitions of key terminology.
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humans actually infectious.
Blood stage vaccines
According to the WHO’s malaria vaccine Rainbow
tables, there are currently at least 15 different sub-unit
candidate vaccines targeting the parasite asexual (blood)
stages in clinical development [20]. There are several
hypothesized mechanisms through which asexual stage
vaccines may function: that antibodies bind parasite
antigens to sufficiently agglutinate and prevent release
of merozoites, or block invasion of erythrocytes leading
to protection against clinical disease and/or its severity
[33-36]; that vaccines such as MSP3 and GLURP would
induce cytophilic classes of antibodies killing parasites
with help from monocytes [37-39]; and that others
(such as PfEMP1, Rifins, Pf332) would enhance splenic
clearance or complement mediated lysis, or diminish
parasite nutrition and growth or reverse endothelial
adherence and glycoprotein binding to result in preven-
tion of toxic effects [8].
In essence, these vaccines are expected to prevent
manifestation, or limit the severity of clinical malaria
disease in immunized individuals, when they get
infected. This was well illustrated in the results of the
trial of malaria vaccine Combination B in Papua New
Guinea, which demonstrated a 62% (95% CI 13-84)
reduction in parasite density in children but no effect
on infection and in fact, a higher incidence of morbid
episodes associated with the variant parasites (with
FC27-type) not covered in the vaccine [39]. One major
foreseeable challenge for vaccine candidates targeting
the blood is strain-specificity of the vaccines antigens
and the extent to which they would cover parasite
polymorphisms encountered in field coupled with the
variability displayed in the cell invasion pathways
P. falciparum[40-43].
On the transmission front however, we can expect
infections to continue within a vaccinated population
for several transmission cycles. The variables m, a, b,
and P in the Macdonald’s formula would be unaffected
(at least during the first encounter following deployment
of the vaccine). The proportion of humans actually
infectious “h” would be reduced while the recovery rate
“r” would greatly increase. All factors remaining the
same, it is plausible that “b”, the sporozoite bites result-
ing in human infection, would be reduced by the next
generation of parasites and eventually reduction in “b”
would substantially contribute lowering R0 within the
vaccinated population. The standard control measures
of early diagnosis and effective chemotherapy would
greatly enhance this impact [30-32,44,45]. Current
Figure 2 The Macdonald mathematical formula.
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dal drugs with independent modes of action and differ-
ent biochemical targets aims at both improving the
efficacy and retarding the development of resistance to
the individual components of the combination. This
concept has been realized in multiple-drug therapy for
leprosy, tuberculosis and cancer and, more recently in
antiretroviral treatments. In malaria, this has also been
the approach with the development of such drugs as
sulphadoxine-pyrimethamine, atovaquone-proguanil,
mefloquine-sulphadoxine-pyrimethamine and lately arte-
misinin-based combinations. In the context of reducing
malaria transmission, drugs that are implicated in game-
tocytogenesis, such as sulphadoxine/pyrimethamine [46]
may actually enhance transmission by causing an
increase in “h”; the proportion of humans actually
infectious.
Sexual stage vaccines
Vaccines targeting the sexual stages of the parasite are
termed transmission-interrupting vaccines because they
would stimulate antibodies that inhibit exflagellation
and fertilization of gametocytes, that render them non-
infectious for the mosquitoes when taken up during a
blood meal [47]. Antibodies could also block the process
by which ookinetes develop into oocysts and prevent
transmission of infectious sporozoites to humans
[47-49]. Examples of potential vaccine antigens like this
include Pfs25, Pfs48/45 and Pfs230. Currently, there is
no candidate vaccine targeting this stage that has made
it to clinical field evaluation, but there are two candi-
dates in pre-clinical evaluation, both of which are based
on Pfs 25 [20].
The hallmark of this category of vaccines is that they
would have no immediate clinical benefit to recipients
in terms of protection against malaria infection and dis-
ease, but will benefit the wider community [1,49]. In
terms of transmission model dynamics, if transmission-
blocking vaccines are effectively and completely
deployed in a population viewed as a homogeneous
compartment, they would disrupt transmission by
shrinking “P”, the survival rate in mosquitoes. By the
next generation of parasites, the proportion of humans
actually having the infection “h” as well as the survival
rate in mosquitoes “P” would be remarkably lowered.
The key challenge to vaccine development here is that
entire populations would have to be immunized and the
vaccine effects should last through several transmission
cycles. However, other vector control measures includ-
ing ITN use, in-door residual spraying, use of repellents
as well as adverse climatic conditions against the mos-
quito vector (such as drought) would greatly enhance
these effects as earlier discussed.
Gauging the expectations
From an epidemiological view point, progress towards
malaria elimination can be viewed in terms of reduction
in disease specific attributable mortality; reductions in
the overall disease burden; the extent to which a disease
under control; proportion to elimination of the disease;
and then eradication and ultimately extinction as shown
in Figure 3.
Aspirations for malaria elimination and eventual eradi-
cation should indeed be the vision or ultimate goal of
any malaria control programme. However, while grap-
pling with high case fatality rates, overwhelming disease
burden and failure to implement or sustain available
control measures, it may be too optimistic, if not unrea-
listic to consider elimination issues in many contexts in
Africa. Figure 3 illustrates in a simplified way, the stages
at which malaria endemic regions may be placed
depending on the level of control, or the lack of it that
the region experiences.
The progress of endemic countries or regions on this
scale is affected by many factors including, but not lim-
ited to; its level of endemicity by entomological inocula-
tion rates, efficiency at implementation of available
tools, social economic situation of the region, health sys-
tems efficiency, climatic conditions as well as political
stability including that of neighbouring regions. There-
fore, the immediate or short to medium term goals of a
particular region should depend on what stage they are
in these series.
So is elimination all wishful thinking?
Interventions using current tools can result in major
reductions in malaria transmission and the associated
disease burden; however, in high transmission settings
they are insufficient to drive prevalence below the pre-
elimination threshold [50]. A malaria vaccine offers,
therefore, great potential for improved malaria control,
particularly in Africa, where effective mosquito control
over long periods has proved difficult or impossible to
maintain [51]. Indeed recent successes in malaria con-
trol using other approaches highlight the need and the
potential gains that could come from an efficacious vac-
cine [8,10]. However, to adequately measure vaccine
impact will require enhanced surveillance and standar-
dized reporting mechanisms. Unfortunately, the large
range of R0 estimates in literature confirms the fact that
malaria control presents variable challenges across its
transmission spectrum and a ‘‘one-size-fits-all’’ malaria
control strategy would be inefficient in the broader con-
text of malaria elimination [16]. Large reductions in
transmission from targeted control are possible only if
p r o g r a m m e sa r ea b l et oi d e n t i f yt h o s ew h oa r eb i t t e n
most, and specific interventions packaged and
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impact reductions to the 1% parasite prevalence thresh-
old in low- to moderate-transmission settings especially
when the main vectors are primarily endophilic (indoor-
resting), provided a comprehensive and sustained inter-
vention programme is efficiently managed. In high-
transmission settings and areas, where vectors are
mainly exophilic (outdoor-resting), additional new tools
that target exophagic (outdoor-biting), exophilic, and
partly zoophagic mosquitoes will be required [50,52,53].
D e p e n d i n go nw h i c hs t a g e( s e eF i g u r e3 )i nc o n t r o la
particular region might be at, specific tailor-made inter-
v e n t i o n sw o u l db er e q u i r e dt om o v ef r o mo n es t a g et o
the next. In areas where R0 is low such as those around
stage 3, local elimination of malaria may be practical
and concerted efforts should focus on that goal [52].
The immediate realistic focus of control should be redu-
cing the mortality and disease burden in general, for
areas where R0 m a yb eh i g hs u c ha st h o s ea r o u n ds t a g e
1 and 2.
On the other hand, the impact of the malaria inter-
ventions should not be limited to the estimated level of
efficacy and coverage alone. The potential impact of
vaccines could generally be wider than expected due to
synergies and doubling of effects, which is hard to theo-
retically predict. For example, RTS,S was observed to
have an impressive reduction in severe disease incidence
in Mozambican children despite being a pre-erythrocytic
stage vaccine [54]. This trial was designed to primarily
assess vaccine efficacy against clinical malaria disease,
which at six months was found be 29·9% (95% CI 11·0–
44·8; p 0·004) while efficacy against severe malaria was
57·7% (95% CI 16·2–80·6; p 0·019). Could synergies
between a partially protective malaria vaccine and cur-
rently available control tools further enhance the impact
of vaccine?
What a malaria vaccine will not do
As the discussion on the possibility of malaria elimi-
nation in some African contexts goes on, it is impera-
tive that expectations from the potential role of an
efficacious vaccine are moderated. To do so, it is
important to consider what not to expect from the
current generation of vaccines in clinical
development:
1. Be 100% protective efficacy: None of the vaccines
currently in clinical development will be close to 100%
protective efficacy. The malaria vaccine Technology
Roadmap rightly predicts that by 2015, the licensed vac-
cine could achieve a 50% reduction in malaria deaths
and severe illness among young children in sub-Saharan
Africa and by 2020, license a vaccine that can achieve
an 80% reduction [55].
2. Be deployed by the vaccine developer: Once an effi-
cacious vaccine is licensed, it will be available to govern-
ments and their Ministries of Health to include in their
control programmes, procure and deploy. African coun-
tries who have had to change their national anti-malarial
drug policy will recognize the complexities of harmoniz-
ing various national treatment guidelines, developing
effective in-service training, ensuring adequate drug sup-
ply and educating the patient population [56,57].
3. Eliminate malaria from countries in stages 1 & 2:
Existing tools may be sufficient to reduce the burden of
disease and bring it under control in many low trans-
mission areas. However, the situation in much of sub-
Saharan Africa is such that partially protective vaccines
currently in clinical development, may not in themselves
bridge the control gap [1,9].
4. Count the numbers to document control and elimi-
nation: The capacity to accurately account for the
impact of malaria vaccines towards elimination will be
critical. Improved surveillance and reporting systems
will be necessary to demonstrate any vaccine impact .
5. Reduce the cost of malaria control: Even if the vac-
cine will ultimately be paid for by donors, sub-Saharan
African governments should expect successful deploy-
ment of a vaccine to come at a cost to their already
strained health budgets. Thus, availability of an effica-
cious (and affordable) malaria vaccine should be viewed
initially as a cost before the rewards of control will be
realized.
Figure 3 Expression of stages of malaria control towards eradication.
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to categorize diseases by their global morbidity and
mortality impact and this has developed substantially
during the last decade, epitomized by the reporting the
Global Burden of Diseases and the Disease Control Prio-
rities project [57,58]. Unfortunately, despite these efforts,
the evidence base for allocating resources for malaria
control on a global scale is still poor [57-59] and no
meaningful improvement will come without affected
regions themselves taking on serious initiatives and
responsibility.
Need to visit the drawing board
Although there is renewed motivation towards malaria
elimination, most of the vaccines currently in the global
portfolio were not conceived in the context of malaria
elimination [43]. The focus on vaccines that are deploy-
able through the expanded programme on immuniza-
tion is certainly useful in targeting the most vulnerable
and most affected by the disease, but may not at all deal
with the reservoir hosts available in older children and
semi immune adults. It does also appear evident that
sub-unit vaccines with a sing l ep a r a s i t ea n t i g e nt a r g e t
may not be sufficient to interrupt malaria transmission
especially in areas with higher than moderate transmis-
sion. To attain to malaria elimination, research and
development must continue even when partially protec-
tive vaccines become available. More efforts on com-
bined and multi-stage vaccines with potent adjuvants
will be necessary ingredients for the malaria elimination
agenda [51].
This call for malaria elimination should be extended
to all stakeholders from funders of malaria vaccine work
through endemic country governments, research institu-
tions, control programmes and down to the individual
family faced with the daily challenge of malaria sickness.
There is need for an entire paradigm shift if malaria
elimination is to eventually be realized and it is not
enough to simply pump more funds into research and
development [57,58]. The mere possibility of having a
vaccine against malaria highlights the fact that there is
now a need, more than ever before, to rethink how to
integrate all available tools and resources towards
malaria elimination.
Conclusion
Is vaccine the magic bullet for malaria elimination?
Probably not today. The global community working
towards malaria control and eventual elimination is
faced with many difficult challenges which cannot be
fixed by a magic bullet. The fact that malaria transmis-
sion and clinical manifestation is so varied demands a
variety of approaches be made in the fight against the
scourge. Strategic planning for malaria control should
consider R0, the spatial scale of transmission and human
population density in tailor-making interventions so that
multiple, integrated and sustained control methods are
focused in populations where R0 is highest [16].
The current efforts for vaccine development have
rightly targeted falciparum malaria, which is the major
cause of morbidity and fatality. However, because Plas-
modium inter-species characteristics are said to be pro-
ducts of evolutionary dynamics, it is important to be
circumspect and not forge tt h ep o s s i b i l i t yo fa“new
malaria problem” (more so with Plasmodium vivax ),
once Plasmodium falciparum is eliminated [62].
The protracted fight against malaria should have
taught us that the parasite is a resilient enemy able to
mount various escape strategies and therefore, it must
be approached with multi pronged approaches. Malaria
vaccines currently in clinical development represent pre-
clinical knowledge and thinking of 10-20 years ago. The
present landscape however, demonstrates the need to
design vaccines with the goal of eliminating and even-
tually eradicating malaria.
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